Cancer Immunology and Immunotherapy Program

癌症免疫学和免疫治疗项目

• 批准号: 10712669
• 负责人: Lawrence Fong
• 金额: $ 18.32万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-05 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712669
• 关键词: Address; Adoptive Cell Transfers; Attention; Back; Biological Models; Biology; Blood; Brain Neoplasms; Cancer Center Support Grant; Catchment Area; Cell Therapy; Cells; Clinic; Clinical; Clinical Investigator; Complement; Data; Development; Disparity; Environment; Genetic Engineering; Goals; Immune; Immune response; Immune system; Immunologic Surveillance; Immunology; Immunotherapeutic agent; Immunotherapy; Laboratories; Lymphoma; Malignant Neoplasms; Malignant neoplasm of lung; Mediating; Molecular; Multiple Myeloma; Myelogenous; Myeloid Cells; Myeloproliferative disease; Non-Hodgkin' s Lymphoma; Patients; Population; Population Heterogeneity; Positioning Attribute; Regulatory T-Lymphocyte; Research; Resistance; Role; Sampling; Science; Scientist; T-Lymphocyte; Techniques; Technology; Therapeutic; Therapeutic Intervention; Training and Education; Translating; Translational Research; Tumor Immunity; Work; cancer immunotherapy; cell type; checkpoint therapy; clinical application; clinical investigation; community engagement; cytokine; engineered T cells; high dimensionality; improved; improved outcome; interest; leukemia; melanoma; member; mouse model; next generation; novel; novel therapeutics; pre-clinical; programs; resistance mechanism; response; therapy resistant; translational study; tumor; tumor immunology; tumor microenvironment; tumor progression

Cancer Immunology and Immunotherapy Program: Summary/Abstract The overarching scientific goal of the Cancer Immunology and Immunotherapy Program (CII) is to advance the understanding of the interplay between the immune system and cancer to discover new strategies for immune- based immunotherapies and to mitigate therapeutic resistance. Overall, CII Program research has led to advances in the understanding of the molecular basis for immune cell recognition of tumors, evasive mechanisms evolved by tumors to escape immune surveillance, how the microenvironment influences the immune response to cancer, and technological advances in genetic engineering of T cells for adoptive cell therapies. The CII Program is a new program since the prior competing renewal. The HDFCCC-wide realignment of research programs enhances opportunities for direct interaction between discovery scientists and clinical investigators within the CII Program and between programs. Research strengths of members include expertise in immunology, immunotherapy, the tumor microenvironment, cellular therapy, and immune therapeutic resistance. The CII Program provides a unique opportunity to address issues related to disparities in the catchment area in leukemia, multiple myeloma, lymphoma, melanoma, and lung cancer, with special attention placed on understanding differences in the overall clinical responses as well as access to novel immunotherapies in this diverse population. CII members are therefore positioned to translate HDFCCC discovery science into the clinic, and to bring clinical observations back to HDFCCC laboratories. Specifically, CII members conduct research to (1) define the mechanistic interplay between cancer and the immune system, (2) advance therapeutic interventions to improve outcomes with cancer immunotherapy, and (3) identify mechanisms of resistance to cancer immunotherapy.

癌症免疫学和免疫治疗计划：摘要/摘要 癌症免疫学和免疫治疗计划（CII）的首要科学目标是促进癌症的免疫治疗。 了解免疫系统和癌症之间的相互作用，以发现免疫的新策略， 基于免疫疗法并减轻治疗抗性。总的来说，CII计划的研究导致了 在肿瘤免疫细胞识别的分子基础的理解的进展，回避 肿瘤进化出逃避免疫监视的机制，微环境如何影响肿瘤细胞的生长， 肿瘤免疫应答及过继性T细胞基因工程技术进展 治疗CII计划是自上一次竞争性更新以来的新计划。HDFCC范围内 研究计划的重新调整增加了发现科学家之间直接互动的机会 以及CII计划内和计划之间的临床研究者。成员的研究优势 包括免疫学，免疫治疗，肿瘤微环境，细胞治疗和免疫 治疗抵抗CII计划提供了一个独特的机会来解决与差距有关的问题 在白血病、多发性骨髓瘤、淋巴瘤、黑色素瘤和肺癌的集水区， 注意理解总体临床反应的差异以及获得新的 免疫疗法在这个多样化的人群中。因此，CII成员能够翻译HDFCCC 将发现科学带入临床，并将临床观察带回HDFCCC实验室。具体地说， CII成员进行研究，以（1）定义癌症和免疫系统之间的相互作用机制， (2)推进治疗干预，以改善癌症免疫治疗的结果，以及（3）确定 对癌症免疫疗法的抵抗机制。